Molecular biology of renal cell carcinoma

Clinical and Translational Oncology

Volumn 8, Issue 10, 2006, Pages 706-710

  Mellado, Begoña ^a   Gascón, Pere ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bevacizumab; Molecular biology; Renal cell carcinoma; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

AXITINIB; BEVACIZUMAB; ERLOTINIB; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; SEMAXANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAF PROTEIN; RAPAMYCIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

CARCINOGENESIS; DRUG TARGETING; GENE INACTIVATION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE; COMPARATIVE STUDY; DRUG ANTAGONISM; EXON; GENETICS; KIDNEY TUMOR; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; EXONS; HIPPEL-LINDAU DISEASE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY; MUTATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RAF KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947669287     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0116-7     Document Type: Review

References (33)

1. Kopper L, Timar J. Genomics of renal cell cancer-does it provide breakthrough? Pathol Oncol Res. 2006:12(1):5-11.
2. Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006;21:9.
3. Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol. 2006;11(3):209-13.
4. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-lalpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function: Implications for targeling the HIF pathway. Cancer Res. 2006; 15;66(12):6264-70.
5. Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther. 2005;5(6):1051-40.
6. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(15):5675-8.
7. Rathmell WK, Hickey MM, Bezman NA, et al. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 2004;64(23):8595-603.
8. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/ -tumors. Mol Cancer Res. 2004;2(2):89-95.
9. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, rognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003;9(13):4641-52.
10. Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem. 2003;278(45):44966-74.
11. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 2006;66(3):1313-9.
12. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33(4):592-406.
13. Reddy GK, Mughal TI, Rini BI. Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced-Stage Renal Cell Carcinoma. Clin Genitourin Cancer. 2006;5(2):110-3.
14. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpresed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci. 2006;36(3):283-93.
15. Morgensztern D, McLeod HL. P13K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797-803.
16. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and-2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int. 2006;98(3):661-7.
17. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R. Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group. Eur Urol. 2006,5.
18. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98(4):756-62.
19. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B, Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int. 2006;97(5):1102-8.
20. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;25(5):1028-43. Epub 2004; 8. Review.
21. Datta K, Mondal S, Sinha S, Li J, Wang E, Knebelmann B, Karumanchi SA, Mukhopadhyay D. Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene. 2005,24(55):7850-8.
22. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol. 2004;14(2):123-30.
23. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93(3):297-302.
24. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, rognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003;15;9(13):4641-52.
25. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-34.
26. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-12.
27. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24.
28. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-24.
29. Pietras K, Sjöblom T, Rubin J, Jeldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3:439-43.
30. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of plateletderived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol. 2003;120(1):107-12.
31. Xu L, Tong R, Cochran DM, Jain RK, Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005;65(13):5711-9.
32. Jermann M, Stahel RA, Salzberg M, et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol. 2006;57(4):533-9.
33. hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;25(31):7889-96.